PandemieGrippaleV1, PubMed, Checkpoint, bibRecord, 000158

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Identifieur interne : 000158 ( PubMed/Checkpoint ); précédent : 000157; suivant : 000159

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Auteurs : Amanda L. Skarlupka [États-Unis] ; Simon O. Owino [États-Unis] ; Lui P. Suzuki-Williams [États-Unis] ; Corey J. Crevar [États-Unis] ; Donald M. Carter [États-Unis] ; Ted M. Ross [États-Unis]

Source :

Human vaccines & immunotherapeutics [ 2164-554X ] ; 2019.

RBID : pubmed:31448974

Descripteurs français

KwdFr :
- Animaux, Anticorps antiviraux (sang), Antigènes viraux (génétique), Antigènes viraux (immunologie), Femelle, Glycoprotéine hémagglutinine du virus influenza (génétique), Glycoprotéine hémagglutinine du virus influenza (immunologie), Grippe humaine (), Grippe humaine (virologie), Humains, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (virologie), Ordinateurs moléculaires, Souris, Souris de lignée BALB C, Sous-type H1N1 du virus de la grippe A, Suidae, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins à pseudo-particules virales (immunologie).
MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza.
- immunologie : Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Vaccins antigrippaux, Vaccins à pseudo-particules virales.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine, Infections à Orthomyxoviridae.
- Animaux, Femelle, Grippe humaine, Humains, Infections à Orthomyxoviridae, Ordinateurs moléculaires, Souris, Souris de lignée BALB C, Sous-type H1N1 du virus de la grippe A, Suidae.

English descriptors

KwdEn :
- Animals, Antibodies, Viral (blood), Antigens, Viral (genetics), Antigens, Viral (immunology), Computers, Molecular, Female, Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Swine, Vaccines, Virus-Like Particle (immunology).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus.
- chemical , immunology : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Virus-Like Particle.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections.
- virology : Influenza, Human, Orthomyxoviridae Infections.
- Animals, Computers, Molecular, Female, Humans, Influenza A Virus, H1N1 Subtype, Mice, Mice, Inbred BALB C, Swine.

Abstract

Swine H1 influenza viruses were stable within pigs for nearly 70 years until in 1998 when a classical swine virus reassorted with avian and human influenza viruses to generate the novel triple reassortant H1N1 strain that eventually led to the 2009 influenza pandemic. Previously, our group demonstrated broad protection against a panel of human H1N1 viruses using HA antigens derived by the COBRA methodology. In this report, the effectiveness of COBRA HA antigens (SW1, SW2, SW3 and SW4), which were designed using only HA sequences from swine H1N1 and H1N2 isolates, were tested in BALB/c mice. The effectiveness of these vaccines were compared to HA sequences designed using both human and swine H1 HA sequences or human only sequences. SW2 and SW4 elicited antibodies that detected the pandemic-like virus, A/California/07/2009 (CA/09), had antibodies with HAI activity against almost all the classical swine influenza viruses isolated from 1973-2015 and all of the Eurasian viruses in our panel. However, sera collected from mice vaccinated with SW2 or SW4 had HAI activity against ~25% of the human seasonal-like influenza viruses isolated from 2009-2015. In contrast, the P1 COBRA HA vaccine (derived from both swine and human HA sequences) elicited antibodies that had HAI activity against both swine and human H1 viruses and protected against CA/09 challenge, but not a human seasonal-like swine H1N2 virus challenge. However, the SW1 vaccine protected against this challenge as well as the homologous vaccine. These results support the idea that a pan-swine-human H1 influenza virus vaccine is possible.

DOI: 10.1080/21645515.2019.1653743
PubMed: 31448974

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000101
to stream PubMed, to step Curation: 000101

Links to Exploration step

pubmed:31448974

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.</title>
<author><name sortKey="Skarlupka, Amanda L" sort="Skarlupka, Amanda L" uniqKey="Skarlupka A" first="Amanda L" last="Skarlupka">Amanda L. Skarlupka</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Owino, Simon O" sort="Owino, Simon O" uniqKey="Owino S" first="Simon O" last="Owino">Simon O. Owino</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Suzuki Williams, Lui P" sort="Suzuki Williams, Lui P" uniqKey="Suzuki Williams L" first="Lui P" last="Suzuki-Williams">Lui P. Suzuki-Williams</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Crevar, Corey J" sort="Crevar, Corey J" uniqKey="Crevar C" first="Corey J" last="Crevar">Corey J. Crevar</name>
<affiliation wicri:level="2"><nlm:affiliation>Vaccine and Gene Therapy Institute of Florida , Port St. Lucie , FL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine and Gene Therapy Institute of Florida , Port St. Lucie , FL </wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, Donald M" sort="Carter, Donald M" uniqKey="Carter D" first="Donald M" last="Carter">Donald M. Carter</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ross, Ted M" sort="Ross, Ted M" uniqKey="Ross T" first="Ted M" last="Ross">Ted M. Ross</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31448974</idno>
<idno type="pmid">31448974</idno>
<idno type="doi">10.1080/21645515.2019.1653743</idno>
<idno type="wicri:Area/PubMed/Corpus">000101</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000101</idno>
<idno type="wicri:Area/PubMed/Curation">000101</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000101</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000158</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000158</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.</title>
<author><name sortKey="Skarlupka, Amanda L" sort="Skarlupka, Amanda L" uniqKey="Skarlupka A" first="Amanda L" last="Skarlupka">Amanda L. Skarlupka</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Owino, Simon O" sort="Owino, Simon O" uniqKey="Owino S" first="Simon O" last="Owino">Simon O. Owino</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Suzuki Williams, Lui P" sort="Suzuki Williams, Lui P" uniqKey="Suzuki Williams L" first="Lui P" last="Suzuki-Williams">Lui P. Suzuki-Williams</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Crevar, Corey J" sort="Crevar, Corey J" uniqKey="Crevar C" first="Corey J" last="Crevar">Corey J. Crevar</name>
<affiliation wicri:level="2"><nlm:affiliation>Vaccine and Gene Therapy Institute of Florida , Port St. Lucie , FL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Vaccine and Gene Therapy Institute of Florida , Port St. Lucie , FL </wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, Donald M" sort="Carter, Donald M" uniqKey="Carter D" first="Donald M" last="Carter">Donald M. Carter</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ross, Ted M" sort="Ross, Ted M" uniqKey="Ross T" first="Ted M" last="Ross">Ted M. Ross</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Vaccines and Immunology, University of Georgia , Athens , GA </wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antigens, Viral (genetics)</term>
<term>Antigens, Viral (immunology)</term>
<term>Computers, Molecular</term>
<term>Female</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Swine</term>
<term>Vaccines, Virus-Like Particle (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Antigènes viraux (génétique)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Femelle</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (virologie)</term>
<term>Ordinateurs moléculaires</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Suidae</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins à pseudo-particules virales (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Virus-Like Particle</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins à pseudo-particules virales</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Computers, Molecular</term>
<term>Female</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Swine</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae</term>
<term>Ordinateurs moléculaires</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Suidae</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Swine H1 influenza viruses were stable within pigs for nearly 70 years until in 1998 when a classical swine virus reassorted with avian and human influenza viruses to generate the novel triple reassortant H1N1 strain that eventually led to the 2009 influenza pandemic. Previously, our group demonstrated broad protection against a panel of human H1N1 viruses using HA antigens derived by the COBRA methodology. In this report, the effectiveness of COBRA HA antigens (SW1, SW2, SW3 and SW4), which were designed using only HA sequences from swine H1N1 and H1N2 isolates, were tested in BALB/c mice. The effectiveness of these vaccines were compared to HA sequences designed using both human and swine H1 HA sequences or human only sequences. SW2 and SW4 elicited antibodies that detected the pandemic-like virus, A/California/07/2009 (CA/09), had antibodies with HAI activity against almost all the classical swine influenza viruses isolated from 1973-2015 and all of the Eurasian viruses in our panel. However, sera collected from mice vaccinated with SW2 or SW4 had HAI activity against ~25% of the human seasonal-like influenza viruses isolated from 2009-2015. In contrast, the P1 COBRA HA vaccine (derived from both swine and human HA sequences) elicited antibodies that had HAI activity against both swine and human H1 viruses and protected against CA/09 challenge, but not a human seasonal-like swine H1N2 virus challenge. However, the SW1 vaccine protected against this challenge as well as the homologous vaccine. These results support the idea that a pan-swine-human H1 influenza virus vaccine is possible.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31448974</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<Issue>9</Issue>
<PubDate><Year>2019</Year>
</PubDate>
</JournalIssue>
<Title>Human vaccines & immunotherapeutics</Title>
<ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
</Journal>
<ArticleTitle>Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.</ArticleTitle>
<Pagination><MedlinePgn>2013-2029</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1653743</ELocationID>
<Abstract><AbstractText>Swine H1 influenza viruses were stable within pigs for nearly 70 years until in 1998 when a classical swine virus reassorted with avian and human influenza viruses to generate the novel triple reassortant H1N1 strain that eventually led to the 2009 influenza pandemic. Previously, our group demonstrated broad protection against a panel of human H1N1 viruses using HA antigens derived by the COBRA methodology. In this report, the effectiveness of COBRA HA antigens (SW1, SW2, SW3 and SW4), which were designed using only HA sequences from swine H1N1 and H1N2 isolates, were tested in BALB/c mice. The effectiveness of these vaccines were compared to HA sequences designed using both human and swine H1 HA sequences or human only sequences. SW2 and SW4 elicited antibodies that detected the pandemic-like virus, A/California/07/2009 (CA/09), had antibodies with HAI activity against almost all the classical swine influenza viruses isolated from 1973-2015 and all of the Eurasian viruses in our panel. However, sera collected from mice vaccinated with SW2 or SW4 had HAI activity against ~25% of the human seasonal-like influenza viruses isolated from 2009-2015. In contrast, the P1 COBRA HA vaccine (derived from both swine and human HA sequences) elicited antibodies that had HAI activity against both swine and human H1 viruses and protected against CA/09 challenge, but not a human seasonal-like swine H1N2 virus challenge. However, the SW1 vaccine protected against this challenge as well as the homologous vaccine. These results support the idea that a pan-swine-human H1 influenza virus vaccine is possible.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skarlupka</LastName>
<ForeName>Amanda L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Owino</LastName>
<ForeName>Simon O</ForeName>
<Initials>SO</Initials>
<AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Suzuki-Williams</LastName>
<ForeName>Lui P</ForeName>
<Initials>LP</Initials>
<AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Crevar</LastName>
<ForeName>Corey J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute of Florida , Port St. Lucie , FL , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Carter</LastName>
<ForeName>Donald M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ross</LastName>
<ForeName>Ted M</ForeName>
<Initials>TM</Initials>
<Identifier Source="ORCID">0000-0003-1947-7469</Identifier>
<AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Georgia , Athens , GA , USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hum Vaccin Immunother</MedlineTA>
<NlmUniqueID>101572652</NlmUniqueID>
<ISSNLinking>2164-5515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039301" MajorTopicYN="N">Computers, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COBRA</Keyword>
<Keyword MajorTopicYN="Y">H1N1</Keyword>
<Keyword MajorTopicYN="Y">hemagglutination-inhibition</Keyword>
<Keyword MajorTopicYN="Y">influenza</Keyword>
<Keyword MajorTopicYN="Y">mice</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31448974</ArticleId>
<ArticleId IdType="doi">10.1080/21645515.2019.1653743</ArticleId>
<ArticleId IdType="pmc">PMC6773400</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>PLoS One. 2014 Nov 12;9(11):e112302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25391151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Elife. 2016 Apr 15;5:e12217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27113719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2016 Dec 15;63(12):1558-1563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27821546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2012 Feb;19(2):128-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22190399</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Curr. 2009 Sep 02;1:RRN1031</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20029613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Sep 7;28 Suppl 4:D33-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20713259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2010 Sep;237(1):117-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20727033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Nov 11;90(2):1116-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26559834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2000 Aug;1(2):127-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11248804</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Electrophoresis. 1997 Dec;18(15):2714-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9504803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Apr 24;8(4):e61397</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23637827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Feb 15;197 Suppl 1:S19-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18269323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Glycobiology. 2015 Jan;25(1):124-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25227423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Res. 2012 Mar 27;43:24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22452923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Microbiol. 2000 May 22;74(1-2):29-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10799776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Yonsei Med J. 2012 Sep;53(5):886-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22869469</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Occup Environ Hyg. 2016 Aug;13(8):577-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26950677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2010 Apr 16;328(5976):357-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20339031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2006 Jan 1;42(1):14-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16323086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Electrophoresis. 2009 Jun;30 Suppl 1:S162-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19517507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2017 Nov 30;91(24):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28978710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2008 Oct 28;5:131</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18957098</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2018 Feb 12;19(1):51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29433425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2002 May 10;85(2):199-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12034486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2009 Nov 24;6:207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19930669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2002 Jun;147(6):1209-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12111430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2012 May 15;205(10):1562-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22448011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2018 May;518:45-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29453058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2016 Apr 14;90(9):4720-4734</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26912624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2012 Oct;93(Pt 10):2195-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22791604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Dec;7 Suppl 4:42-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24224819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mSphere. 2016 Dec 14;1(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27981236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2012 Jun 15;28(12):1647-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22543367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Apr 5;29(16):3043-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21320540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2011 Jun;7(6):e1002077</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21695237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Genes. 2010 Feb;40(1):28-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19862613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Eng Des Sel. 2011 Mar;24(3):291-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21123189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Prev Vet Med. 2017 Mar 1;138:55-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28237236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2008;72:127-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19081490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2015 Apr 2;201:24-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25701742</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Sep;86(17):9221-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22718832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2011 Apr;92(Pt 4):919-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21177926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2019 Apr 2;10(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30940704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2018 Sep 28;13(9):e0204284</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30265682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29109276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Genes. 2009 Oct;39(2):176-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19597980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27899672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Methods. 2011 Dec 25;9(2):173-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22198341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29788355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2002 Mar;40(3):1073-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11880444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 1997 Sep 1;25(17):3389-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9254694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2010 Mar 24;2(24):24ra21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20375007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Feb;77(3):2046-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12525639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Jun;98(3):476-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23583287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2014 Mar 14;6(3):1294-316</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24638204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1981 Jul 2;292(5818):72-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7278968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Feb;87(3):1400-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23115287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2017 Nov 30;91(24):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28978709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Eng Des Sel. 2009 Sep;22(9):543-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19578121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1993 Mar;193(1):503-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8438586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2011 Feb 1;27(3):343-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21134891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2013 Jul 29;210(8):1493-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23857983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2019 Jan 17;93(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30429350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2012 Nov;93(Pt 11):2326-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22971819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2009 Dec 15;10:421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20003500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biol. 1997 Nov 3;139(3):613-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9348279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1991 Jun;182(2):475-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2024485</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Géorgie (États-Unis)</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Skarlupka, Amanda L" sort="Skarlupka, Amanda L" uniqKey="Skarlupka A" first="Amanda L" last="Skarlupka">Amanda L. Skarlupka</name>
</region>
<name sortKey="Carter, Donald M" sort="Carter, Donald M" uniqKey="Carter D" first="Donald M" last="Carter">Donald M. Carter</name>
<name sortKey="Crevar, Corey J" sort="Crevar, Corey J" uniqKey="Crevar C" first="Corey J" last="Crevar">Corey J. Crevar</name>
<name sortKey="Owino, Simon O" sort="Owino, Simon O" uniqKey="Owino S" first="Simon O" last="Owino">Simon O. Owino</name>
<name sortKey="Ross, Ted M" sort="Ross, Ted M" uniqKey="Ross T" first="Ted M" last="Ross">Ted M. Ross</name>
<name sortKey="Suzuki Williams, Lui P" sort="Suzuki Williams, Lui P" uniqKey="Suzuki Williams L" first="Lui P" last="Suzuki-Williams">Lui P. Suzuki-Williams</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000158 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000158 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:31448974
   |texte=   Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:31448974" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki